The Filing Desk

AdvanSix vs Innospec

AdvanSix ASIX · Innospec IOSP · Specialty Chemicals

Innospec reported revenue of $1.8 billion in fiscal 2025, 1.2 times AdvanSix's $1.5 billion in fiscal 2025. AdvanSix's revenue grew 0.3% in its latest year, and Innospec's fell 3.6%. Free cash flow was $6 million at AdvanSix and $88 million at Innospec.

Side by side

AdvanSixInnospec
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$1.5B$1.8B
Revenue growth0.3%−3.6%
Revenue growth a year, last 5 years5.6%8.3%
Gross margin10.8%27.7%
Operating margin—7.3%
Net margin3.2%6.6%
Free cash flow$6M$88M
Free cash flow margin0.4%5.0%
Return on capital7.1%11.1%
Net debt to EBITDA−0.1x−1.7x
Dividends and buybacks$19M$66M
Change in diluted share count0.3%−0.5%
Last close$15.68$80.39
P/E at the last close—14.2×
Insider trades, last 12 months—bought $52,684, sold $398,854
Piotroski F-score6 of 96 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
AdvanSixInnospec
Operating margin
Percent of revenue
AdvanSixInnospec
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AdvanSixInnospec

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the AdvanSix and Innospec pages.